http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109288843-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ae36d84ea4af395b8f5b7a4d46ec880 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2018-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_120c9682697da7f2f93b371af599ee4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2fc15f32d9eab0cbb423671a13a4132 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad12bd9a2ac101988e29c385e0d4b5de |
| publicationDate | 2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109288843-A |
| titleOfInvention | The hypolipidemic effect of evodiamine |
| abstract | The invention discloses the hypolipidemic effect of evodiamine. Evodialine achieves the purpose of lowering blood lipids by increasing the cholesterol efflux of human THP-1 macrophages, and its effect of regulating cholesterol efflux is due to inhibiting the degradation of ABCA1 protein and activating the TRPV1 receptor. The beneficial effect of the invention is to provide a new target for the prevention and treatment of atherosclerosis, and to provide a convenient way for the research and development of new blood lipid-lowering drugs or health products in the future. |
| priorityDate | 2018-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 132.